Cointime

Oricell Therapeutics

company

About

OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.

  • 101 - 250

Highlights

Total Funding Amount
¥203M $120M
Funding Rounds
3
Investors
6

Details

Last Funding Type
Series A
Last Funding Money Raised
¥200M
Industries
Health Care,Pharmaceutical,Product Research
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

OriCell Therapeutics develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥203M $120M
Oricell Therapeutics has raised a total of ¥203M $120M in funding over 2 rounds. Their latest funding was raised on Aug 1, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 1, 2022 Series B $120M 4 — — Detail
Jan 18, 2021 Series A ¥200M 1 — — Detail
Jun 12, 2018 Angel ¥3M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
6
Oricell Therapeutics is funded by 6 investors. Suzhou Fund and Boquan Equity Investment Management are the most recent investors.
Investor Name Lead Investor Funding Round
Suzhou Fund — Series B
Boquan Equity Investment Management — Series B
J One Capital — Series B
Shanghai Sci-Tech Innovation Center Capital — Series B
Shanghai Gaosen Asset Management — Series A
Suishi Ziben — Angel
Cointime
เนื้อหา
บริษัท